On June 29, 2020, Clarivate Analysis released the 2019 Journal Citation Reports, and Cancer Communications was awarded the impact factor (IF) of 5.627. This marks an important milestone in the journal’s history as is the first time that Cancer Communications has overcome the IF: 5.0 barrier, ranking it as 49th among 244 distinguished oncological journals, worldwide, and has been promoted to the Q1 category. Compared with the 2018 IF rankings, Cancer Communications has greatly improved, demonstrating immense progress made in terms of academic quality, and publication level. It is currently at the forefront of Asian academic oncological journals and has become the highest impact factor journal in the field of oncology, in China.
Cancer Communications (former title: the Chinese Journal of Cancer) is an academic oncological journal sponsored by Sun Yat-sen University Cancer Center (SYSUCC, Guangzhou, China). With the support of strong scientific research resources from SYSUCC and partnership with the highly-acclaimed publisher, Wiley, Cancer Communications is recognized as a key platform for scientific publications in the field of oncology. It is included in PubMed/Medline, SCI, Scopus, and other international databases. Cancer Communications has published more than 1,000 papers from nearly 2,106 institutions in 88 countries/regions, and these papers have been cited over 23,000 times by research institutions in 108 countries/regions and prominent researchers.
Cancer Communications thank all its authors and Peer-Reviewers for their tremendous efforts and contributions, without which this could not have happened. With this new high reached, the Editorial board is even more determined to strive for academic excellence and faster Peer-Reviewed publications.